Skip to main content

Recombinant Proteins Market Size Report 2021-2028 | Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Analysis

Written by Customer Service on . Posted in Mergers And Acquisitions.

Leading Companies in Recombinant Proteins Market are Sigma Aldrich Company Ltd., Novoprotein Scientific, Thermo Fisher Scientific, Merck KGaA, Abcam PLC, Lonza, GenScript Biotech Corporation, ProSpec Tany TechnoGene, Ltd.

Pune, India, Oct. 11, 2021 (GLOBE NEWSWIRE) — The global recombinant proteins market size is projected to experience dynamic growth in the forthcoming years owing to the increasing prevalence of chronic diseases across the world, finds Fortune Business Insights™ in its report, titled “Recombinant Proteins Market, 2021-2028”.

The recombinant proteins come with antibodies, hormones, enzymes, and others which provide various therapies for the treatment of numerous diseases such as diabetes, cancer, and others. There has been an increasing prevalence of chronic diseases such as cancer, and others, which has resulted in high demand for recombinant proteins as these proteins are useful in drug development and research. Thus, this is a vital factor contributing to the growth of this market during the forecast period.

However, the biopharmaceutical companies are undergoing some challenges in getting the regulatory approval, which is projected to impede the growth of this market.

In spite of the COVID-19 pandemic, there has been a high demand for recombinant proteins from the pharmaceutical and healthcare industries across the world. Thus, this pandemic has no major impact on the growth of recombinant proteins market, which acts as a driving factor for this market’s growth.


Get Sample PDF Brochure:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/recombinant-proteins-market-103492


List of Key Players in Recombinant Proteins Market:

  • Sigma Aldrich Company Ltd.
  • Novoprotein Scientific
  • Thermo Fisher Scientific
  • Merck KGaA, Abcam PLC
  • Lonza, GenScript Biotech Corporation
  • ProSpec Tany TechnoGene, Ltd.

Market Segmentation:

On the basis of type, this market is divided into hormones, growth factors, antibody, enzyme, and others. By end-user, the market is classified into biopharmaceutical companies, academic and research institutes, and others. Based on application, the market is categorized into therapeutic and research. In terms of geography, the market is clubbed into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Highlights/Summary:

The report incorporates actionable insights into the regional prospects of the market and provides a comprehensive analysis of the market drivers and challenges. Further, the report also contains detailed bifurcation of key market players and careful study of their strategies and offers a granular evaluation of the different market segments.


To get to know more about the short-term and long-term impact of COVID-19 on this market,

Please Visit: https://www.fortunebusinessinsights.com/recombinant-proteins-market-103492


Drivers/Restraints:

Increasing Investments in Drug Development and Discovery to Fuel the Market

In recent years, there have been increasing investments in drug development and discovery process by the government in which the recombinant proteins play an important role. There are several applications of recombinant proteins such as chemical production, pharmaceutical, cosmetics, and others. Thus, this is a crucial factor responsible for the growth of this market across several regions.

Regional Insights:

Increasing Research and Development Activities in Biotechnology Industry to Boost the North America Market Growth

North America region is projected to dominate the recombinant proteins market share on account of the increasing research and development activities in biotechnology and pharmaceutical industries in this region.

Asia Pacific region is anticipated to grow rapidly in this market due to the rising sales of the products in the use of research and development experiments in this region.


Ask for Customization of this Report:

https://www.fortunebusinessinsights.com/enquiry/customization/recombinant-proteins-market-103492


Competitive Landscape:

Increasing Research in Drug Development to Feed Competition

The leading companies in the recombinant proteins market are focusing on increasing their research activities in drug development due to a high demand for recombinant proteins from the healthcare industry. This has resulted in the increasing competition among key companies which will help them to widen their business operations and strengthen their market foothold.

Industry Development:

June 2020: Lonza launched a new media GSv9 to support the recombinant proteins production using Lonza’s GS Gene Expression System.


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

LinkedIn: https://www.linkedin.com/company/fortune-business-insights

Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.